The inhibition of SGs by targeting eIF2α kinases HRI or PERK could improve the sensitivity of cancer cells to SG-inducing anticancer drugs [26,29,32], indicating that SG inhibitors could be employed as a therapeutic strategy to promote the efficacy of cancer treatment and alleviate anticancer drug resistance. Here, EIF2AK3 is linked to cancer.